论文部分内容阅读
本文报道一种抗髓系细胞分化抗原单抗HI98,属于 IgM,与90%以上人外周血粒细胞,72%单核细胞和56%骨髓细胞反应。与一些上皮细胞有交叉反应。HI98单抗能抑制胎肌浸液诱导的人 GM-CFU 集落形成,最大抑制率达75%。用基因重组的 IL3和 GM-CSF纯品研究证实 HI98单抗只能特异性地抑制IL3诱导的 GM-CFU 和 BFU-E 集落形成,而对 GM-CSF 诱导的 GM-CFU 和 BFU-E 集落形成没有影响。因而生物学试验的结果与Lewis 在今年维也纳会议上报告的 IL3结合抑制试验结果完全一致,表明 HI98单抗的特异性是针对人类 IL3受体,一是一个抗 IL3受体抗体;在国内外尚未见报道。为研究人 IL3受体的基因调控及其与造血细胞增殖、分化、癌变之间的关系和造血因子间的相互作用提供了一个重要的工具。
This article reports an anti-myeloid cell differentiation antigen monoclonal antibody HI98 that belongs to IgM and reacts with more than 90% of human peripheral blood neutrophils, 72% of monocytes and 56% of myeloid cells. Cross-reaction with some epithelial cells. HI98 monoclonal antibody could inhibit the formation of human GM-CFU colonies induced by fetal muscle infusion, the maximum inhibition rate of 75%. Pure recombinant IL-3 and GM-CSF studies confirmed that HI98 mAbs specifically inhibited IL-induced GM-CFU and BFU-E colony formation, whereas GM-CSF induced GM-CFU and BFU-E colonies Forming no effect. The results of the biological assay are therefore in good agreement with the results of the IL3 binding inhibition test reported by Lewis at this year’s Vienna conference, indicating that the specificity of the HI98 monoclonal antibody is against the human IL3 receptor and that of an anti-IL3 receptor antibody; See report. It provides an important tool for studying gene regulation of human IL3 receptor and its relationship with hematopoietic cell proliferation, differentiation, carcinogenesis and hematopoietic factors.